Terms ending in 2035
Every in-force patent on Ablynx N.V.'s record whose computed term ends in 2035, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,637,542 | CX3CR1-TARGETING Imaging Agents and Their Use in the Diagnosis and Treatment of Disease In force · High confidence | Ablynx N.V. | In force | High confidence | |
| US 11,220,539 | Immunoglobulin Variable Domains In force · High confidence | Sanofi | In force | High confidence | |
| US 11,312,764 | Immunoglobulin Variable Domains In force · High confidence | Sanofi | In force | High confidence | |
| US 11,312,765 | Immunoglobulin Variable Domains In force · High confidence | Sanofi | In force | High confidence | |
| US 11,485,777 | Immunoglobulin Variable Domains In force · High confidence | Sanofi | In force | High confidence | |
| US 11,485,778 | Immunoglobulin Variable Domains In force · High confidence | Sanofi | In force | High confidence | |
| US 11,708,404 | Immunoglobulin Variable Domains In force · High confidence | Sanofi | In force | High confidence | |
| US 12,180,268 | Improved Immunoglobulin Variable Domains In force · High confidence | Sanofi | In force | High confidence | |
| US 12,723,072 | Immunoglobulin Variable Domains In force · High confidence | Sanofi | In force | High confidence | |
| US RE50,682 | Immunoglobulin Variable Domains In force · Low confidence | Ablynx N.V. | In force | Low confidence | |
| 2 more term ends in 2035 · Pro | |||||
10 of 12 patents shown. Soonest term end first, then patent number.
Pro members see all 12.
7 of these are in force and held by Ablynx N.V..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.